#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Myxofibrosarcoma Hereditary haemorrhagic telangiectasia Non-small cell lung cancer recurrent Acute graft versus host disease in skin Non-small cell lung cancer metastatic Mantle cell lymphoma recurrent Orthostatic hypotension Gastrointestinal cancer metastatic Chondrosarcoma metastatic Nephroblastoma Desmoid tumour Hereditary angioedema Candida infection Encephalopathy neonatal Chronic myeloid leukaemia (in remission) More trials…

    Learn about Rare Diseases

    Synovial sarcoma Paraneoplastic neurological syndrome – Life with Disease Familial amyotrophic lateral sclerosis – Basic Information Hereditary angioedema – Life with Disease Osteosarcoma recurrent – Life with Disease Andersen-Tawil syndrome – Life with Disease Urea cycle disorder – Diagnostics Chondrosarcoma metastatic – Diagnostics Langerhans’ cell histiocytosis – Diagnostics Von Willebrand’s disease – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Paxalisib Canis Familiaris (553) S230815-2 ZINC CHLORIDE Camonsertib Dantrolene Sodium TRV045 Calcium Levofolinate Bdc-1001 Vedolizumab Enomimeran RO7288817 Cefoxitin Sarilumab SIPAVIBART GSK4418959A TAZAROTENE Progesterone Ph. Eur. Dalteparin Sodium Diltiazem Hydrochloride More therapies…

    Learn about Your Condition

    Lymphangiosarcoma Medullary thyroid cancer Syphilis Niemann-Pick disease Endolymphatic hydrops Small fibre neuropathy B-cell lymphoma Transplantation complication Benign neoplasm of ureter Post procedural complication Haemolytic uraemic syndrome Infectious pleural effusion Acarodermatitis Hyperparathyroidism secondary Arthralgia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Parc Tauli Hospital Universitari

Parc Tauli Hospital Universitari

Parc Del Tauli 1, Sabadell, 08208, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • Cabotegravir and Rilpivirine Ultra‑Long‑Acting vs Long‑Acting in Adults and Adolescents with HIV Who Are Virally Suppressed

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HIV infection
    Investigated Drugs:
    • Cabotegravir
    • Rilpivirine
    Spain

  • A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

    Recruiting

    3 1
    Investigated Drugs:
    • Bi 1015550
    • 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
    Austria Belgium Bulgaria Croatia Czechia Denmark +15

  • Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Nemolizumab
    Bulgaria Croatia France Greece Italy Poland +1

  • Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

    Recruiting

    3 1 1
    Investigated Drugs:
    • Sarilumab
    • Prednisone
    Austria Belgium Czechia France Germany Greece +3

  • Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

    Recruiting

    3 1 1
    Investigated Diseases:
    • Asthma
    Investigated Drugs:
    • Indacaterol Acetate
    • Salbutamol
    • Glycopyrronium Bromide
    France Germany Hungary Poland Romania Slovakia +1

  • EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Denmark Finland France Germany +5

  • Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

    Recruiting

    3 1
    Investigated Diseases:
    • Psoriatic arthropathy
    Investigated Drugs:
    • Zasocitinib
    Belgium Bulgaria Croatia Czechia Estonia France +7

  • Mesalazine Monotherapy vs Continuing Thiopurines in Older Patients with Ulcerative Colitis in Long-Term Remission

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Mesalazine
    Spain

  • Study to evaluate the efficacy and safety of personalized tissue engineered veins in patients with severe chronic venous insufficiency

    Recruiting

    4 1 1
    Investigated Drugs:
    • ALLOGENEIC VEIN TISSUE SEGMENT, DECELLULARISED, WITH A FUNCTIONAL VALVE PERFUSED WITH AUTOLOGOUS PERIPHERAL BLOOD
    Spain

  • A study to evaluate the safety of MRM-3379 in men with Fragile X Syndrome

    Recruiting

    2 1
    Spain
1 2 3 … 29
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!